| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
William Pridgen last filed a Form 4 in February 2024, as Director at DWTX. William Pridgen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, William Pridgen's trades have earned a below-average insider score of 28/100 across 9 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -82.3%.
At the last filing, the largest reported position was 52,045 shares of DWTX. Net of sales, the DWTX filings show accumulation of 52,987 shares.
William Pridgen has 15 Form 4 filings on record from December 2020 to February 2024, all as Director at Dogwood Therapeutics (DWTX), 2020–2024.
The 16 reported transactions were 11 open-market purchases, 4 option or other derivative awards and 1 option exercise.
Counted by filing, the open-market trades come to 11 purchases worth about $232K and no sales.
The largest open-market purchase was 13,450 shares of DWTX at an average $4.38 on May 17, 2022, about $59K. Twelve months later DWTX was down 77%.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2023 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 15,335 | $1.30 | $19,992.24 | +41.8% | -42.8% | -84.6% | |
| May 18, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 241 | $4.50 | $1,084.50 | +0.7% | +46.8% | -75.9% | |
| May 17, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 13,450 | $4.38 | $58,913.69 | +58.4% | +85.0% | -77.0% | |
| Mar 29, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 600 | $4.94 | $2,964.48 | +2.7% | -12.5% | -92.5% | |
| Mar 23, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 2,197 | $5.46 | $12,001.55 | +10.9% | -19.4% | -94.1% | |
| Jan 27, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 4,180 | $5.98 | $24,997.65 | +28.7% | -33.8% | -94.4% | |
| Jan 3, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 2,215 | $5.43 | $12,033.87 | +18.0% | -16.8% | -95.8% | |
| Dec 21, 2021 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 8,827 | $5.66 | $49,997.01 | +252.2% | -2.1% | -95.8% | |
| Jul 7, 2021 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 942 | $6.32 | $5,950.61 | +0.1% | -21.3% | -31.0% | |
| Jan 29, 2021 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 3,500 | $7.47 | $26,145.00 | New | - | - |